Larry Gold
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aptamers, Nucleotide | 10 | 2024 | 88 | 2.080 |
Why?
| | RNA | 24 | 2020 | 926 | 1.690 |
Why?
| | SELEX Aptamer Technique | 7 | 2016 | 16 | 1.240 |
Why?
| | Proteomics | 12 | 2024 | 1203 | 1.150 |
Why?
| | T-Phages | 15 | 1991 | 18 | 1.070 |
Why?
| | Nucleic Acid Conformation | 33 | 2000 | 724 | 1.000 |
Why?
| | Base Sequence | 53 | 2003 | 2123 | 0.990 |
Why?
| | RNA, Catalytic | 4 | 2020 | 191 | 0.980 |
Why?
| | Molecular Sequence Data | 53 | 2012 | 2838 | 0.930 |
Why?
| | Escherichia coli | 23 | 1997 | 832 | 0.900 |
Why?
| | Proteome | 8 | 2024 | 520 | 0.800 |
Why?
| | Oligoribonucleotides | 10 | 1997 | 53 | 0.720 |
Why?
| | Viral Proteins | 14 | 1997 | 351 | 0.700 |
Why?
| | DNA, Single-Stranded | 7 | 2003 | 119 | 0.670 |
Why?
| | Ligands | 22 | 2016 | 678 | 0.650 |
Why?
| | Proteins | 10 | 2023 | 1022 | 0.650 |
Why?
| | Ribonucleotides | 1 | 2020 | 27 | 0.620 |
Why?
| | Biomarkers | 9 | 2015 | 4340 | 0.610 |
Why?
| | RNA, Messenger | 16 | 2017 | 2791 | 0.610 |
Why?
| | Ribosomes | 12 | 1995 | 196 | 0.600 |
Why?
| | Oligonucleotides | 5 | 2023 | 155 | 0.590 |
Why?
| | Oligodeoxyribonucleotides | 8 | 2003 | 141 | 0.580 |
Why?
| | Reverse Transcriptase Inhibitors | 6 | 1996 | 89 | 0.560 |
Why?
| | Blood Proteins | 4 | 2017 | 239 | 0.540 |
Why?
| | Genes, Viral | 11 | 1995 | 88 | 0.490 |
Why?
| | Peptide Chain Initiation, Translational | 6 | 1995 | 43 | 0.470 |
Why?
| | Binding Sites | 23 | 2000 | 1309 | 0.450 |
Why?
| | Protein Biosynthesis | 10 | 1997 | 449 | 0.440 |
Why?
| | RNA, Viral | 10 | 2000 | 693 | 0.410 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2015 | 93 | 0.410 |
Why?
| | HIV-1 | 8 | 1996 | 913 | 0.410 |
Why?
| | Q beta Replicase | 4 | 1996 | 4 | 0.390 |
Why?
| | RNA, Ribosomal | 1 | 2014 | 168 | 0.380 |
Why?
| | DNA | 4 | 2011 | 1421 | 0.370 |
Why?
| | Diagnosis | 2 | 2013 | 16 | 0.360 |
Why?
| | Capsid | 3 | 2000 | 94 | 0.360 |
Why?
| | Bacteriophage T4 | 4 | 1997 | 15 | 0.350 |
Why?
| | Protein Binding | 14 | 2023 | 2244 | 0.330 |
Why?
| | Kinetics | 14 | 2010 | 1553 | 0.320 |
Why?
| | Polymerase Chain Reaction | 15 | 2000 | 1031 | 0.310 |
Why?
| | Gene Products, rev | 2 | 2002 | 6 | 0.300 |
Why?
| | HIV Reverse Transcriptase | 5 | 1996 | 32 | 0.300 |
Why?
| | DNA-Directed DNA Polymerase | 3 | 1997 | 48 | 0.280 |
Why?
| | History, 20th Century | 3 | 2015 | 330 | 0.270 |
Why?
| | Evolution, Molecular | 4 | 2020 | 502 | 0.270 |
Why?
| | Capsid Proteins | 2 | 2000 | 94 | 0.270 |
Why?
| | Information Systems | 3 | 1998 | 58 | 0.270 |
Why?
| | RNA, Bacterial | 4 | 2000 | 183 | 0.270 |
Why?
| | Biological Evolution | 5 | 2014 | 471 | 0.260 |
Why?
| | Bacterial Proteins | 4 | 1996 | 980 | 0.250 |
Why?
| | RNA, Transfer | 4 | 1991 | 142 | 0.240 |
Why?
| | RNA-Binding Proteins | 4 | 2000 | 465 | 0.240 |
Why?
| | RNA Processing, Post-Transcriptional | 4 | 1996 | 92 | 0.240 |
Why?
| | DNA Primers | 10 | 2012 | 487 | 0.230 |
Why?
| | Directed Molecular Evolution | 2 | 1996 | 28 | 0.230 |
Why?
| | DNA-Binding Proteins | 5 | 1993 | 1468 | 0.230 |
Why?
| | Bacteriophages | 2 | 2000 | 110 | 0.220 |
Why?
| | RNA-Directed DNA Polymerase | 5 | 1996 | 35 | 0.220 |
Why?
| | Protein Array Analysis | 3 | 2014 | 56 | 0.220 |
Why?
| | Cloning, Molecular | 11 | 1998 | 526 | 0.210 |
Why?
| | Clinical Laboratory Techniques | 2 | 2003 | 96 | 0.210 |
Why?
| | Gene Library | 2 | 2010 | 121 | 0.210 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2010 | 752 | 0.200 |
Why?
| | Tenascin | 1 | 2003 | 15 | 0.200 |
Why?
| | Templates, Genetic | 6 | 2003 | 63 | 0.190 |
Why?
| | Amino Acid Sequence | 9 | 2003 | 2092 | 0.190 |
Why?
| | Peptide Initiation Factors | 3 | 1993 | 16 | 0.180 |
Why?
| | DNA, Bacterial | 5 | 1997 | 319 | 0.180 |
Why?
| | Biomarkers, Tumor | 3 | 2012 | 1339 | 0.170 |
Why?
| | Protein Interaction Mapping | 1 | 2002 | 105 | 0.170 |
Why?
| | Codon | 7 | 1994 | 92 | 0.170 |
Why?
| | Plasmids | 6 | 1992 | 373 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2002 | 195 | 0.170 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3416 | 0.170 |
Why?
| | Bacteriophage lambda | 3 | 1992 | 89 | 0.170 |
Why?
| | Genomic Library | 2 | 2000 | 15 | 0.170 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2000 | 17 | 0.150 |
Why?
| | Aptamers, Peptide | 2 | 2011 | 3 | 0.150 |
Why?
| | Genome, Bacterial | 1 | 2000 | 122 | 0.150 |
Why?
| | Antibodies | 3 | 2014 | 400 | 0.150 |
Why?
| | Substrate Specificity | 6 | 2000 | 389 | 0.150 |
Why?
| | Neoplasm Proteins | 1 | 2003 | 444 | 0.150 |
Why?
| | Gene Expression Regulation | 6 | 2002 | 2599 | 0.150 |
Why?
| | Structure-Activity Relationship | 7 | 2002 | 563 | 0.140 |
Why?
| | Recombinant Proteins | 7 | 2014 | 1361 | 0.140 |
Why?
| | Mass Spectrometry | 4 | 2010 | 729 | 0.140 |
Why?
| | Nucleic Acids | 2 | 2011 | 78 | 0.130 |
Why?
| | Computer Simulation | 3 | 1998 | 1014 | 0.130 |
Why?
| | Humans | 30 | 2024 | 146342 | 0.130 |
Why?
| | Chloramphenicol | 1 | 1997 | 11 | 0.130 |
Why?
| | Peptidyl Transferases | 1 | 1997 | 8 | 0.130 |
Why?
| | Erythrocyte Membrane | 1 | 1998 | 55 | 0.130 |
Why?
| | Antiviral Agents | 2 | 1995 | 779 | 0.130 |
Why?
| | Ribosomal Proteins | 2 | 1995 | 93 | 0.130 |
Why?
| | DNA, Viral | 4 | 1993 | 354 | 0.130 |
Why?
| | S-Adenosylmethionine | 1 | 1997 | 58 | 0.130 |
Why?
| | Binding, Competitive | 5 | 1996 | 185 | 0.120 |
Why?
| | Guanosine Monophosphate | 1 | 1996 | 8 | 0.120 |
Why?
| | Gene Products, gag | 1 | 1996 | 38 | 0.120 |
Why?
| | Bradykinin | 1 | 1996 | 49 | 0.120 |
Why?
| | Molecular Biology | 1 | 1997 | 59 | 0.120 |
Why?
| | Endpoint Determination | 1 | 2017 | 84 | 0.120 |
Why?
| | Models, Molecular | 4 | 2012 | 1574 | 0.120 |
Why?
| | Repressor Proteins | 3 | 1996 | 430 | 0.120 |
Why?
| | Nucleic Acid Hybridization | 2 | 2010 | 175 | 0.120 |
Why?
| | DNA Nucleotidyltransferases | 1 | 1995 | 11 | 0.110 |
Why?
| | DNA Replication | 3 | 1993 | 248 | 0.110 |
Why?
| | RNA, Antisense | 2 | 1992 | 18 | 0.110 |
Why?
| | Base Composition | 4 | 1996 | 81 | 0.110 |
Why?
| | Endoribonucleases | 1 | 1996 | 80 | 0.110 |
Why?
| | Adenosine | 1 | 1997 | 256 | 0.110 |
Why?
| | Nerve Growth Factors | 1 | 1995 | 79 | 0.110 |
Why?
| | Substance P | 1 | 1995 | 37 | 0.110 |
Why?
| | Models, Theoretical | 1 | 1998 | 561 | 0.110 |
Why?
| | Eye Diseases | 1 | 2016 | 100 | 0.110 |
Why?
| | Ribonucleases | 1 | 1994 | 49 | 0.110 |
Why?
| | Consensus Sequence | 5 | 2000 | 73 | 0.100 |
Why?
| | Transcription, Genetic | 5 | 2000 | 1432 | 0.100 |
Why?
| | Origin of Life | 1 | 2014 | 8 | 0.100 |
Why?
| | RNA, Transfer, Amino Acid-Specific | 1 | 1994 | 4 | 0.100 |
Why?
| | Selenocysteine | 1 | 1994 | 5 | 0.100 |
Why?
| | RNA, Transfer, Amino Acyl | 1 | 1994 | 9 | 0.100 |
Why?
| | Peptide Elongation Factors | 1 | 1994 | 15 | 0.100 |
Why?
| | Ophthalmology | 1 | 2016 | 122 | 0.100 |
Why?
| | Hydrolysis | 4 | 1997 | 195 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 823 | 0.100 |
Why?
| | Escherichia coli Proteins | 1 | 1996 | 200 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 846 | 0.100 |
Why?
| | Genetic Techniques | 2 | 2010 | 64 | 0.100 |
Why?
| | Catalysis | 3 | 2002 | 304 | 0.100 |
Why?
| | Operator Regions, Genetic | 2 | 1990 | 8 | 0.100 |
Why?
| | Genetic Vectors | 2 | 1992 | 327 | 0.100 |
Why?
| | Sensitivity and Specificity | 4 | 2010 | 1998 | 0.100 |
Why?
| | Models, Genetic | 3 | 1991 | 540 | 0.100 |
Why?
| | History, 21st Century | 1 | 2014 | 224 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 38 | 0.090 |
Why?
| | Genes, pX | 1 | 1992 | 2 | 0.090 |
Why?
| | Deoxyribonuclease EcoRI | 1 | 1992 | 4 | 0.090 |
Why?
| | Drug Therapy | 1 | 2013 | 85 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 1195 | 0.090 |
Why?
| | Affinity Labels | 2 | 2014 | 16 | 0.090 |
Why?
| | Body Fluids | 1 | 2012 | 70 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2015 | 3647 | 0.090 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 194 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 4 | 1993 | 326 | 0.090 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2011 | 19 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 1 | 1993 | 507 | 0.080 |
Why?
| | Mutation | 7 | 1995 | 4093 | 0.080 |
Why?
| | Ribonucleotide Reductases | 1 | 1991 | 29 | 0.080 |
Why?
| | Sequence Homology, Nucleic Acid | 4 | 1995 | 157 | 0.080 |
Why?
| | DNA Transposable Elements | 1 | 1992 | 125 | 0.080 |
Why?
| | Biological Assay | 1 | 2011 | 133 | 0.080 |
Why?
| | Chromosome Deletion | 1 | 1991 | 127 | 0.080 |
Why?
| | Transcription Factors | 2 | 1989 | 1730 | 0.080 |
Why?
| | Introns | 1 | 1991 | 257 | 0.080 |
Why?
| | Genes, Regulator | 1 | 1989 | 34 | 0.080 |
Why?
| | Micrococcal Nuclease | 1 | 1989 | 26 | 0.070 |
Why?
| | Promoter Regions, Genetic | 3 | 1991 | 1242 | 0.070 |
Why?
| | Animals | 7 | 2014 | 38107 | 0.070 |
Why?
| | Databases, Protein | 1 | 2009 | 88 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 1996 | 914 | 0.070 |
Why?
| | Exodeoxyribonucleases | 1 | 1988 | 23 | 0.070 |
Why?
| | Neoplasms | 2 | 2012 | 2954 | 0.070 |
Why?
| | Metalloproteins | 1 | 1987 | 6 | 0.070 |
Why?
| | Trans-Activators | 1 | 1990 | 372 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2488 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2675 | 0.070 |
Why?
| | Avian Myeloblastosis Virus | 3 | 1996 | 4 | 0.060 |
Why?
| | Glomerular Filtration Rate | 1 | 2010 | 745 | 0.060 |
Why?
| | Societies | 1 | 2007 | 40 | 0.060 |
Why?
| | Computational Biology | 2 | 2003 | 678 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 731 | 0.060 |
Why?
| | Cohort Studies | 2 | 2015 | 6077 | 0.060 |
Why?
| | Genes, Bacterial | 2 | 2000 | 151 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2004 | 534 | 0.060 |
Why?
| | Oligonucleotide Probes | 3 | 1991 | 48 | 0.060 |
Why?
| | Sequence Analysis | 2 | 1996 | 32 | 0.060 |
Why?
| | Peptide Fragments | 2 | 2003 | 693 | 0.060 |
Why?
| | Conserved Sequence | 2 | 1997 | 242 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1432 | 0.060 |
Why?
| | Early Detection of Cancer | 1 | 2010 | 506 | 0.050 |
Why?
| | Mathematics | 2 | 1998 | 102 | 0.050 |
Why?
| | Membrane Proteins | 2 | 2003 | 1130 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2010 | 589 | 0.050 |
Why?
| | Zinc | 1 | 1987 | 310 | 0.050 |
Why?
| | Macromolecular Substances | 2 | 1996 | 205 | 0.050 |
Why?
| | Models, Biological | 1 | 1991 | 1761 | 0.050 |
Why?
| | DNA, Fungal | 2 | 1997 | 76 | 0.050 |
Why?
| | RNA, Transfer, Met | 2 | 1994 | 6 | 0.050 |
Why?
| | Molecular Structure | 2 | 2012 | 484 | 0.050 |
Why?
| | Hydrogen Bonding | 2 | 1994 | 170 | 0.050 |
Why?
| | beta-Galactosidase | 3 | 1994 | 73 | 0.050 |
Why?
| | Restriction Mapping | 2 | 1995 | 80 | 0.050 |
Why?
| | Ultraviolet Rays | 2 | 1996 | 376 | 0.050 |
Why?
| | Selection, Genetic | 2 | 1998 | 269 | 0.050 |
Why?
| | Spin Labels | 1 | 2023 | 60 | 0.050 |
Why?
| | Human Genome Project | 1 | 2003 | 15 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2023 | 97 | 0.050 |
Why?
| | Isomerism | 2 | 1992 | 55 | 0.050 |
Why?
| | Drug Design | 2 | 1995 | 180 | 0.050 |
Why?
| | United States | 2 | 2015 | 16136 | 0.050 |
Why?
| | Education, Continuing | 1 | 2003 | 42 | 0.050 |
Why?
| | Gene Expression | 3 | 1992 | 1463 | 0.050 |
Why?
| | Adenosine Triphosphate | 2 | 1997 | 494 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2003 | 882 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2003 | 453 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2014 | 104 | 0.040 |
Why?
| | Complement System Proteins | 2 | 2017 | 326 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 771 | 0.040 |
Why?
| | Cross-Linking Reagents | 2 | 2004 | 208 | 0.040 |
Why?
| | RNA, Fungal | 2 | 1991 | 71 | 0.040 |
Why?
| | Prokaryotic Initiation Factor-3 | 2 | 1990 | 6 | 0.040 |
Why?
| | In Vitro Techniques | 2 | 1995 | 1041 | 0.040 |
Why?
| | Genome | 1 | 2002 | 307 | 0.040 |
Why?
| | Glioblastoma | 1 | 2003 | 350 | 0.040 |
Why?
| | Artifacts | 1 | 2000 | 143 | 0.040 |
Why?
| | Child, Preschool | 1 | 2015 | 11913 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 2 | 1997 | 584 | 0.040 |
Why?
| | Genetic Variation | 2 | 2017 | 996 | 0.040 |
Why?
| | Machine Learning | 1 | 2024 | 594 | 0.030 |
Why?
| | Young Adult | 1 | 2015 | 14330 | 0.030 |
Why?
| | RNA, Ribosomal, 23S | 1 | 1997 | 12 | 0.030 |
Why?
| | DNA Mutational Analysis | 2 | 1990 | 410 | 0.030 |
Why?
| | International Cooperation | 2 | 2009 | 193 | 0.030 |
Why?
| | Genomics | 1 | 2003 | 853 | 0.030 |
Why?
| | Male | 3 | 2015 | 73396 | 0.030 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 1996 | 10 | 0.030 |
Why?
| | Peptide Elongation Factor Tu | 1 | 1996 | 5 | 0.030 |
Why?
| | Uridine Triphosphate | 1 | 1996 | 9 | 0.030 |
Why?
| | Butanones | 1 | 1996 | 3 | 0.030 |
Why?
| | Alkylation | 1 | 1996 | 27 | 0.030 |
Why?
| | Replicon | 1 | 1996 | 12 | 0.030 |
Why?
| | Thionucleotides | 1 | 1996 | 35 | 0.030 |
Why?
| | NAD | 1 | 1997 | 80 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2017 | 110 | 0.030 |
Why?
| | Metals | 1 | 1997 | 137 | 0.030 |
Why?
| | Heme | 1 | 2017 | 90 | 0.030 |
Why?
| | Gene Dosage | 1 | 1997 | 146 | 0.030 |
Why?
| | Sulfur | 1 | 1996 | 60 | 0.030 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 6 | 0.030 |
Why?
| | Single-Strand Specific DNA and RNA Endonucleases | 1 | 1995 | 10 | 0.030 |
Why?
| | Immunodeficiency Virus, Feline | 1 | 1996 | 34 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2012 | 693 | 0.030 |
Why?
| | Aldehydes | 1 | 1996 | 140 | 0.030 |
Why?
| | Buffers | 1 | 1995 | 56 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 176 | 0.030 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 1995 | 42 | 0.030 |
Why?
| | Viral Structural Proteins | 1 | 1995 | 12 | 0.030 |
Why?
| | Adolescent | 1 | 2015 | 22557 | 0.030 |
Why?
| | Sepharose | 1 | 1995 | 32 | 0.030 |
Why?
| | RNA Splicing | 1 | 2017 | 288 | 0.030 |
Why?
| | Arginine | 1 | 1996 | 264 | 0.030 |
Why?
| | Child | 1 | 2015 | 22693 | 0.030 |
Why?
| | Virus Integration | 1 | 1995 | 69 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1997 | 627 | 0.030 |
Why?
| | Glycoproteins | 1 | 2017 | 356 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1994 | 87 | 0.030 |
Why?
| | Sodium Chloride | 1 | 1995 | 138 | 0.030 |
Why?
| | Ribonuclease H | 1 | 1994 | 12 | 0.030 |
Why?
| | Leukemia Virus, Murine | 1 | 1994 | 17 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 388 | 0.030 |
Why?
| | Integrases | 1 | 1995 | 117 | 0.030 |
Why?
| | Genome, Human | 1 | 2017 | 431 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 319 | 0.030 |
Why?
| | Viruses | 1 | 1996 | 165 | 0.030 |
Why?
| | Selenoproteins | 1 | 1994 | 7 | 0.030 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 1994 | 18 | 0.030 |
Why?
| | RNA, Transfer, Phe | 1 | 1993 | 9 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1994 | 269 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 487 | 0.030 |
Why?
| | Models, Structural | 1 | 1993 | 40 | 0.030 |
Why?
| | Aged | 2 | 2012 | 26432 | 0.020 |
Why?
| | Alleles | 1 | 2017 | 907 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 377 | 0.020 |
Why?
| | Rho Factor | 1 | 1993 | 4 | 0.020 |
Why?
| | Electrophoresis | 1 | 1992 | 31 | 0.020 |
Why?
| | Chromatography, Affinity | 1 | 1993 | 82 | 0.020 |
Why?
| | Transition Temperature | 1 | 2012 | 27 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1993 | 371 | 0.020 |
Why?
| | Software | 1 | 1998 | 676 | 0.020 |
Why?
| | RNA, Small Untranslated | 1 | 2012 | 14 | 0.020 |
Why?
| | Allosteric Regulation | 1 | 1992 | 102 | 0.020 |
Why?
| | Lac Operon | 1 | 1992 | 42 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2012 | 218 | 0.020 |
Why?
| | Titrimetry | 1 | 2011 | 12 | 0.020 |
Why?
| | Random Allocation | 1 | 1992 | 366 | 0.020 |
Why?
| | Complement Inactivating Agents | 1 | 2013 | 78 | 0.020 |
Why?
| | Middle Aged | 2 | 2012 | 36619 | 0.020 |
Why?
| | Adult | 1 | 2015 | 41087 | 0.020 |
Why?
| | Limit of Detection | 1 | 2011 | 92 | 0.020 |
Why?
| | Nanotechnology | 1 | 2012 | 114 | 0.020 |
Why?
| | Ion Channels | 1 | 1992 | 128 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 1992 | 144 | 0.020 |
Why?
| | Automation | 1 | 2011 | 104 | 0.020 |
Why?
| | Sequence Analysis, RNA | 1 | 1994 | 441 | 0.020 |
Why?
| | Anticodon | 1 | 1991 | 24 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2012 | 477 | 0.020 |
Why?
| | Endodeoxyribonucleases | 1 | 1991 | 77 | 0.020 |
Why?
| | Triticum | 1 | 1990 | 18 | 0.020 |
Why?
| | Sequence Alignment | 1 | 1991 | 360 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 1991 | 202 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 287 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 504 | 0.020 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1990 | 92 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 1992 | 368 | 0.020 |
Why?
| | Germany | 1 | 1990 | 139 | 0.020 |
Why?
| | Placenta | 1 | 1997 | 794 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1537 | 0.020 |
Why?
| | Tetrahydrofolate Dehydrogenase | 1 | 1989 | 22 | 0.020 |
Why?
| | Databases, Factual | 1 | 1995 | 1493 | 0.020 |
Why?
| | Database Management Systems | 1 | 2009 | 50 | 0.020 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1989 | 90 | 0.020 |
Why?
| | Nervous System Diseases | 1 | 2012 | 288 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1992 | 663 | 0.020 |
Why?
| | Exodeoxyribonuclease V | 1 | 1988 | 6 | 0.020 |
Why?
| | Open Reading Frames | 1 | 1989 | 130 | 0.020 |
Why?
| | Genes | 1 | 1988 | 215 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1724 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1987 | 72 | 0.020 |
Why?
| | RNA Caps | 1 | 1988 | 33 | 0.020 |
Why?
| | Gene Conversion | 1 | 1987 | 7 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2009 | 253 | 0.020 |
Why?
| | Models, Statistical | 1 | 2010 | 669 | 0.010 |
Why?
| | Female | 2 | 2012 | 79499 | 0.010 |
Why?
| | Europe | 1 | 2007 | 421 | 0.010 |
Why?
| | Virus Replication | 1 | 1987 | 526 | 0.010 |
Why?
| | Endostatins | 1 | 2004 | 10 | 0.010 |
Why?
| | Interleukin-16 | 1 | 2004 | 6 | 0.010 |
Why?
| | Lod Score | 1 | 2004 | 64 | 0.010 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 26 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1991 | 1512 | 0.010 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2004 | 93 | 0.010 |
Why?
| | Smoking | 1 | 2010 | 1486 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 728 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2439 | 0.010 |
Why?
| | Autoantibodies | 1 | 2010 | 1500 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1849 | 0.010 |
Why?
| | Risk Factors | 1 | 2017 | 10921 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2004 | 259 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 545 | 0.010 |
Why?
| | Light | 1 | 2004 | 401 | 0.010 |
Why?
| | Inflammation | 1 | 2012 | 2919 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2022 | 0.010 |
Why?
| | Moloney murine leukemia virus | 1 | 1996 | 12 | 0.010 |
Why?
| | Zidovudine | 1 | 1996 | 75 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1996 | 116 | 0.010 |
Why?
| | Cats | 1 | 1996 | 226 | 0.010 |
Why?
| | Virion | 1 | 1996 | 112 | 0.010 |
Why?
|
|
Gold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|